GenVec, Inc. (GNVC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.47-0.02 (-3.06%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.49
Bid0.00 x
Ask0.57 x 10000
Day's Range0.45 - 0.51
52wk Range0.35 - 3.69
1y Target EstN/A
Market Cap10.8M
P/E Ratio (ttm)-1.37
Avg Vol (3m)127,662
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    GenVec To Present At 2016 Cell & Gene Meeting On The Mesa

    GAITHERSBURG, Md., Sept. 28, 2016 /PRNewswire/ -- GenVec, Inc. (GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present "Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies",  a brief review of GenVec's technology platform, at the 2016 Cell & Gene Meeting on the Mesa (CGMOM).  This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene delivery to immune system cells, including T cells. GenVec believes that these vectors can be applied for therapeutic approaches focusing on genetically modified human primary T cells. GenVec has extensive expertise translating innovative product concepts from the laboratory to the clinic.

  • American City Business Journalslast month

    GenVec faces delisting threat after it fails to raise share price

    Gaithersburg-based GenVec Inc. is facing the threat of market delisting, but for now it has a bit more time to raise its share price. The gene delivery company (GNVC) first received a warning from the Nasdaq Stock Market in February because its share price was below the $1 minimum for 30 consecutive days.

  • GenVec, Inc. :GNVC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
    Capital Cube2 months ago

    GenVec, Inc. :GNVC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016

    Categories: Yahoo Finance Click here to see latest analysis GenVec, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Sangamo BioSciences, Inc., Astrazeneca PLC Sponsored ADR and Johnson & Johnson ... Read more (Read more...)